Thermo Fisher Scientific Inc. $TMO Shares Sold by MUFG Securities EMEA plc

MUFG Securities EMEA plc cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 15,402 shares of the medical research company’s stock after selling 11,826 shares during the period. MUFG Securities EMEA plc’s holdings in Thermo Fisher Scientific were worth $8,925,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after acquiring an additional 288,296 shares during the period. Capital World Investors increased its position in shares of Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock valued at $4,988,132,000 after acquiring an additional 706,572 shares during the period. Geode Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after acquiring an additional 26,425 shares during the period. Franklin Resources Inc. increased its position in shares of Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after acquiring an additional 1,028,125 shares during the period. Finally, Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $3,072,744,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. Barclays cut their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. Robert W. Baird cut their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $616.10.

Insider Activity

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $492.34 on Monday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market cap of $182.96 billion, a price-to-earnings ratio of 27.07, a PEG ratio of 2.18 and a beta of 0.88. The firm’s fifty day moving average is $479.94 and its two-hundred day moving average is $534.34.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the company earned $5.15 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.